Skip to main content
Premium Trial:

Request an Annual Quote

Natera Prices $250M Public Stock Offering

NEW YORK – Natera said late on Thursday that it has priced the $250 million public stock offering announced earlier this week. The company is offering 4,166,666 shares of its common stock at a price of $60 per share.

The follow-on offering is expected to close on Sept. 15, subject to customary closing conditions.

The underwriters have a 30-day option to purchase up to another 624,999 shares of Natera's common stock at the public offering price, less the underwriting discounts and commissions.

As previously announced, JP Morgan, Morgan Stanley, Cowen, and SVB Leerink are acting as joint book-running managers for the offering, while Baird and Craig-Hallum Capital Group are acting as co-managers.

In morning trading on the Nasdaq, Natera's stock was down 3 percent, at $59.83 per share.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.